Show simple item record

dc.contributor.authorLipcsey, Miklos
dc.contributor.authorTenhunen, Jyrki
dc.contributor.authorPischke, Soeren
dc.contributor.authorKuitunen, Anne
dc.contributor.authorFlaatten, Hans
dc.contributor.authorDe Geer, Lina
dc.contributor.authorSjölin, Jan
dc.contributor.authorFrithiof, Robert
dc.contributor.authorChew, Michelle S.
dc.contributor.authorBendel, Stepani
dc.contributor.authorKawati, Rafael
dc.contributor.authorLarsson, Anders
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorTønnessen, Tor Inge
dc.contributor.authorRubertsson, Sten
dc.date.accessioned2021-02-17T10:18:21Z
dc.date.available2021-02-17T10:18:21Z
dc.date.created2020-01-13T09:56:41Z
dc.date.issued2020
dc.identifier.citationShock. 2020, 54 (2), 224-231.en_US
dc.identifier.issn1073-2322
dc.identifier.urihttps://hdl.handle.net/11250/2728624
dc.description.abstractPurpose: Lipopolysaccharides (LPS) are presumed to contribute to the inflammatory response in sepsis. We investigated if extracorporeal Alteco LPS Adsorber for LPS removal in early gram-negative septic shock was feasible and safe. Also, effects on endotoxin level, inflammatory response, and organ function were assessed. Methods: A pilot, double-blinded, randomized, Phase IIa, feasibility clinical investigation was undertaken in six Scandinavian intensive care units aiming to allocate 32 septic shock patients with abdominal or urogenital focus on LPS Adsorber therapy or a Sham Adsorber, therapy without active LPS binding. The study treatment was initiated within 12 h of inclusion and given for 6 h daily on first 2 days. LPS was measured in all patients. Results: The investigation was terminated after 527 days with eight patients included in the LPS Adsorber group and seven in the Sham group. Twenty-one adverse effects, judged not to be related to the device, were reported in three patients in the LPS Adsorber group and two in the Sham group. Two patients in the Sham group and no patients in the LPS Adsorber group died within 28 days. Plasma LPS levels were low without groups differences during or after adsorber therapy. The changes in inflammatory markers and organ function were similar in the groups. Conclusions: In a small cohort of patients with presumed gram-negative septic shock, levels of circulating endotoxin were low and no adverse effects within 28 days after LPS adsorber-treatment were observed. No benefit compared with a sham device was seen when using a LPS adsorber in addition to standard care.en_US
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.titleEndotoxin removal in septic shock with the Alteco LPS Adsorber was safe but showed no benefit compared to placebo in the double-blind randomized controlled trial - the Asset Studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.source.pagenumber224-231en_US
dc.source.volume54en_US
dc.source.journalShocken_US
dc.source.issue2en_US
dc.identifier.doi10.1097/SHK.0000000000001503
dc.identifier.cristin1771083
dc.relation.projectNorges forskningsråd: 223255en_US
dc.description.localcodeLocked until 30.8.2021 due to copyright restrictionsen_US
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record